Alembic Pharmaceuticals Limited · NSE:APLLTD

Alembic Pharmaceuticals — Investor Presentation (October 2016)

16 slides from Alembic Pharmaceuticals's investor presentation, October 2016

  1. Slide 1: Alembic Pharmaceuticals Ltd Investor Presentation

    Alembic Pharmaceuticals Ltd Investor Presentation October-2016

  2. Slide 2: Contents

    Contents 1. Milestones 2. Quarterly Highlights 3. Half yearly Highlights 4. Business - International - India Branded 5. Strategy 6. Financials - Annual - Latest Quarter

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe

  4. Slide 4: Milestones

    Milestones 1907 Established by Amin family 2006 FDA approves API facilities 2007 Acquired Dabur’s Indian cardiology, GI and gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed. 2012 Formed a JV for NCE research Launched first NDA

  5. Slide 5: Quarterly Highlights – Q2 FY17

    Quarterly Highlights – Q2 FY 17 Financial Highlights India Branded Formulations (Rs. 3383 mn)  Net Sales at Rs 8787 mn  Business grew by 19%  Acute segment grew by 22% and Specialty  EBITDA margins at 20% at Rs 1778 mn segment grew 16%  Net Profit at Rs 1187 mn  R&D spend is Rs 1151 mn for the

  6. Slide 6: Quarterly Highlights – H1 FY17

    Quarterly Highlights – H1 FY 17 Financial Highlights India Branded Formulations (Rs. 6161 mn)  Net Sales at Rs 16145 mn  Business grew by 13%  Specialty Segment grew by 16% and Acute  EBITDA margins at 21% at Rs 3347 mn Segment grew by 7%.  Net Profit at Rs 2207 mn  Strengthening the share of

  7. Slide 7: Business

    Business Sales CAGR% Rs 15bn Rs 32bn 21% Manufacturing: 16% 25% API 9% Formulation: Baddi and Sikkim for India market 38% FDA approved Oral Solids in Vadodara Doubled capacity in 2014 53% India 12% API: 3 FDA approved facilities in Vadodara 46% Expansion in 2015 22% International 46% FY12 FY16 R&D:

  8. Slide 8: International Formulations

    International Formulations Sales (Rs bn) ANDA Filed Filings: 82 Approval: 49* 14.6 13 * Incl 6 tentative CAGR 46% 8 7 7 5.6 5.9 4 3.2 3.0 FY12 FY13 FY14 FY15 FY16 FY12 FY13 FY14 FY15 FY16 R&D Spend (Rs bn) Milestones and Update 10.9 7.0 6.7 4.8 5.1  Focus on day-1 launches 3.5 Aripiprazole R&D%  U

  9. Slide 9: India Branded

    India Branded Sales (Rs bn) Marketing Organisation CAGR 14% 11.0 9.8  5000 + marketing team 8.5 Added 1000 over last two years 7.5 6.6  17 marketing divisions Added new divisions in gynaecology, cardiology , GI, urology  170 products Launch 20-25 products every year FY12 FY13 FY14 FY15 FY16 Thera

  10. Slide 10: Therapy-wise Performance Q2 FY17

    Therapy-wise Performance Q2 FY17 SEP QTR 2016 SEP QTR 2015 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share Growth Growth Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) (ORG) (ORG) (ORG) (PRIM) Cardiology 8 2.09 20 17 17 1.88 35 33 Anti Diabetic 16 1.84 43 28 2

  11. Slide 11: Strategy

    Strategy Competitive position Growth drivers Skills US: Rapidly expand breadth and quality of pipeline Doubled internal OSD grid, half of grid is external – injectable, dermatology and ophtahalmics High Partnerships to gain time and leverage financial resource Build manufacturing capacities rapidly,

  12. Slide 12: Financials – 5 years

    Financials – 5 years Sales (Rs bn) EBITDA (Rs bn) Margins% 32% 31.8 17% 19% 19% CAGR 21% 15% 10.1 20.7 18.7 14.7 15.3 4.0 3.6 2.2 2.5 FY12 FY13 FY14 FY15 FY16 FY12 FY13 FY14 FY15 FY16 Net Profit (Rs bn) Capital employed (Rs bn) 23% ROCE% 53% 31% 40% 30% Margins% 13% 14% 25% 11% 7.2 9% 17.8 11.9 2.8

  13. Slide 13: Financials - Quarter

    Financials - Quarter Sales (Rs bn) EBITDA (Rs bn) 10.2 3.8 8.8 1.8 Q2FY16 Q2FY17 Q2FY16 Q2FY17 PAT (Rs bn) Business Sales 2.9 40% 56% International India 41% API 1.2 30% 13% 19% Q2FY16 Q2FY17 Q2FY16 Q2FY17

  14. Slide 14: Financials – Half yearly

    Financials – Half yearly Sales (Rs bn) EBITDA (Rs bn) 16.1 16.1 4.8 3.4 H1FY16 H1FY17 H1FY16 H1FY17 PAT (Rs bn) Business Sales 3.6 47% 41% International 2.2 India 41% 37% API 16% 18% H1FY16 H1FY17 H1FY16 H1FY17

  15. Slide 15: Latest Shareholding Pattern

    Latest Shareholding Pattern % of Total Shareholding 12 Promoter & Promoter group 14 FI/FII/MF Public 74 Market capitalization INR 123 bn Total paid-up share capital 377.03mn Total number of shares O/S 188.52mn No. of shareholders >50 K Free float market INR 32 bn capitalization

  16. Slide 16: Thank You

    THANK YOU

Alembic Pharmaceuticals — Investor Presentation (October 2016) on 6ix